A COMMITMENT TO EXCELLENCE
We are committed to expanding our role as the world’s leader in delivering intelligent devices and biologics that diagnose, treat, and monitor patients with severe heart failure, cardiovascular and peripheral vascular diseases.
| || || || |
Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.
MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.
The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart.
Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells. Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.
The BioHeart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing innovative treatment and management of patients with severe cardiovascular and peripheral vascular disease.
| || |
President & CEO
Mike Tomás, CEO of BioHeart, is considered by many in the industry as one of the most experienced marketers and operating executives for IT/Communications and Biotech/Life Sciences private equity and venture groups portfolio companies. The son of a serial entrepreneur, he spent nearly 20 years driving the evolution of telecommunications in the U.S. and Mexico in leadership roles ranging from sales, marketing, customer service, telemarketing, engineering, and operations. Upon retiring as Chief Marketing Officer of Avantel, MCI/Worldcom's Global Ventures $1B investment with Banamex (at the time, the largest bank in Latin America), Mr Tomás joined other former-MCI executives (including MCI CEO Jerry Taylor) and helped raise venture capital to form Ineto, an integrated customer communications software solution that was named on Red Herring magazine’s “Top Ten to Watch” list. Mr Tomás sits on the boards of Avisena (revenue cycle management company for medical practices), Perimeter Internetworking (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner--and winner of top communications, medical innovations, education and entrepreneurial awards. An avid athlete, he is also a Miami-Dade County Sports Commissioner.
**Important: Mike Tomás' personal StemCellCEO blog!**
| || |
Chief Scientific Officer
Ms. Comella has over 15 years’ experience in corporate entities with expertise in regenerative medicine. She was recently named number 24 according to Terrapin’s list of the Top 50 Global Stem Cell Influencers. Ms. Comella has pioneered a variety of stem cell therapies including cord blood derived cells, bone marrow cells, muscle cells and adipose cells for use in many different applications. She has developed a wide range of regenerative products and techniques that have been successfully implemented into the clinic. She also led the team that gained the first ever FDA approval for clinical trials using a combined cell and gene therapy product. Ms. Comella has been a member of the Bioheart Inc. senior management team since 2004 and is currently serving as the Chief Scientific Officer and board member. Bioheart is a publically traded company focusing on the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases. Since joining Bioheart, she has played a major role in managing the product development, manufacturing and quality systems of cellular products. In addition, Ms. Comella is currently and actively serving on multiple boards in the stem cell arena. She was co-founder and Chief Executive Officer of Stemlogix, LLC for veterinary medicine. Ms. Comella has years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy. Previously, she worked as a research engineer for Osiris Therapeutics developing stem cell therapies for osteoarthritis. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.
| || |
Dr. William P. Murphy, Jr.
Dr. William P. Murphy, Jr., currently serves the Chairman of the Board of Bioheart, having joined the as a member of the Board of Directors in June 2003. A highly successful entrepreneur and inventor, the owner of 17 patents, a distinguished speaker and published author, Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was later acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which filed for involuntary bankruptcy in December 2003.
Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology. Dr. Murphy is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology and the Jay Malina Award from the Beacon Council, Miami-Dade County’s economic development arm.
Executive Officers and Directors
Set forth below is information regarding our executive officers and directors as of March 26, 2012
| || || || || || 47 || || || |
Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D.
| || || || || 89 || || || |
Director, Chairman of the Board
| || || || || || 77 || || || |
| || || || || || 58 || || || |
| || || || || || 52 || || || |
| || || || || || 59 || || || |
| || || || || || 35 || || || |
Director*, Chief Scientific Officer
| || On March 12, 2013, Richard T. Spencer III resigned as a member of the Board of Directors. On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors to serve until the next annual meeting, her earlier resignation or death. |
The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve this objective, we plan to pursue the following key strategies:
| || Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. |
| || Obtain regulatory approval of MyoCell and/or MyoCell SDF-1 to treat patients with less severe heart damage. If we obtain initial regulatory approval of MyoCell for the Class III Subgroup, we intend to continue to sponsor clinical trials in an effort to demonstrate that MyoCell and/or MyoCell SDF-1 should receive regulatory approval to treat all patients in NYHA Class II, Class III and Class IV heart failure and, provided we believe we have a reasonable basis to support such an indication, we intend to seek regulatory approval for these patients. |
| || Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. In parallel with our efforts to secure regulatory approval of MyoCell, we intend to continue to develop and test other product candidates for the treatment of chronic and acute heart damage. These efforts are expected to initially focus on the MyoCell SDF-1 product candidate. |
| || Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes. |
| || Expand and enhance our intellectual property rights. We intend to expand and enhance our intellectual property rights. |
| || License, acquire and/or develop complementary products and technologies. We intend to strengthen and expand our product development efforts through the license, acquisition and/or development of products and technologies that support our business strategy. |
BHRT - Daily Candlesticks
Participate in a short, annonymus BHRT survey here; http://investorshub.advfn.com/boards/board_survey.asp?board_id=12025